Key result
Pharmacoinvasive therapy with prourokinase before PCI significantly increased the rate of an opened infarct-related artery on arrival compared to primary PCI alone (48% vs. 21%, P=0.0002).
Why the study?
Does pharmacoinvasive therapy with prourokinase improve angiographic parameters and clinical outcomes compared to primary PCI alone in STEMI patients with expected long PCI-related delay?
RCT (n=197)
Yes
Does pharmacoinvasive therapy with prourokinase improve angiographic parameters and clinical outcomes compared to primary PCI alone in STEMI patients with expected long PCI-related delay?
Absolute Event Rate: 48% vs 21%
p-value: p=0.0002
A pharmacoinvasive strategy using prourokinase prior to PCI significantly improves initial infarct-related artery patency and myocardial perfusion in STEMI patients facing long PCI delays.
No takes yet. Share an insight, caveat, or question.
Supports pharmacoinvasive prourokinase before PCI in delayed STEMI; extends RCT evidence for facilitated reperfusion.
Han et al. (2013) conducted an RCT in ST-segment elevation myocardial infarction (STEMI) (n=197). Prourokinase (prouk-PCI) vs. Primary PCI was evaluated on Opened infarct-related artery on arrival (p=0.0002). Pharmacoinvasive therapy with prourokinase before PCI significantly increased the rate of an opened infarct-related artery on arrival compared to primary PCI alone (48% vs. 21%, P=0.0002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: